European Commission approves Roche ’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer

Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq ® (atezolizumab) in combination with chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]), for the initial (first-line) treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news